Factor VIII inhibitor bypass activity (FEIBA) for the reduction of transfusion in cardiac surgery: a randomized, double-blind, placebo-controlled, pilot trial

Table 5 Safety and adverse events, number of events (%)

	FEIBA n = 6	Placebo n = 6
Number of patients with AEs	2	0
30-day mortality	2 (33)	0
Cerebrovascular accident	2 (33)	0
Thromboembolism	0	0
Deep vein thrombosis/pulmonary embolism	0	0
Myocardial infarction	0	0
Renal replacement therapy	1 (17)	0

ISSN: 2055-5784